Navigation Links
Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
Date:10/26/2007

Analysis of study showed effect size of VYVANSE ranged from 1.39 to 1.73

BOSTON, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced results from an analysis of VYVANSE(TM) (lisdexamfetamine dimesylate) effect size. These findings were presented today at a national meeting of psychiatrists in Boston. Effect size is a standardized and scientific method of comparing effectiveness of medications evaluated in different studies for the same condition. In general, effect sizes are categorized as small (0.2), medium (0.5) and large (0.8).

An analysis of the phase III pivotal study in pediatric patients with Attention Deficit Hyperactivity Disorder (ADHD) showed the effect size of VYVANSE was 1.39, 1.42 and 1.73 for 30 mg, 50 mg and 70 mg, respectively. This analysis was conducted to establish that the effect size of VYVANSE was due to the medication's effectiveness and not due to two potential influencing factors: the precision of measurement as indexed by standard deviation of endpoint scores, and the size of baseline versus endpoint placebo effect. The findings show that neither of these factors played a role in determining the effect size of VYVANSE. The relationship between effect size and clinical benefit has not been established.

"I'm encouraged that in our analysis, VYVANSE showed a large effect size," said Stephen Faraone, Ph.D., director of medical genetics research and head of child and adolescent psychiatry research at SUNY Upstate Medical University, who led the analysis. "This further supports our belief that VYVANSE is an effective treatment option for children with ADHD."

VYVANSE is a prodrug of d-amphetamine and is approved in the U.S. for the treatment of ADHD in children aged 6 to 12 years.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diag
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), a ... that Thomas M. Patton , President and ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, at ... . The presentation is scheduled to begin ... will be available via a live webcast at http://wsw.com/webcast/marcum/casm/ ...
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... CARLSBAD, Calif. , May 23, 2013 Isis ... antisense therapeutics, today announced that management will present a company ... Health Care Conference on Thursday, May 30, 2013 at 8:40 ... A live audio webcast of the presentation will be ... Web site, www.isispharm.com .  A replay will be available ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Company (NYSE: ADM ) is pleased to ... effects of soy isoflavones in the alleviation of menopausal ... by Menopause: The Journal of The North American ... soy isoflavone supplements, like NovaSoy brand soy isoflavones, are ...
... /PRNewswire-iReach/ -- Global BioClinical (GBC) the Seattle-based contract ... a new website at www.globalbioclinical.com . The ... offered, partner registration, new search capabilities, and links ... The service descriptions function as a benchmark ...
Cached Medicine Technology:Study Confirms Soy Isoflavones Reduce Menopausal Hot Flashes 2Study Confirms Soy Isoflavones Reduce Menopausal Hot Flashes 3Global BioClinical Launches New Website 2
(Date:5/23/2013)... Camden, New Jersey (PRWEB) May 23, 2013 ... million Americans suffering from irritable bowel syndrome (IBS), the ... damper on your holiday fun. , “While hot dogs ... picnic plate during the warm weather months, IBS sufferers ... foods,” says Deborah Sokol, MD, a gastroenterologist with Lourdes ...
(Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Transvaginal ... Bard, Inc., continue to move forward in a federal ... of West Virginia, Bernstein Liebhard LLP reports. In ... a request by C.R. Bard to seal emails that ... secrets and other confidential, proprietary information about its suppliers. ...
Breaking Medicine News(10 mins):Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3
... of Knowledge Award in the Biomedicine category goes in ... New York, United States), investigator in the Department of ... granted, in the words of the jury, "for his ... the largest, most versatile and most therapeutically accessible receptor ...
... research , WEDNESDAY, Jan. 27 (HealthDay News) -- Same-sex couples ... couples are, a review of 20 years of social science ... out there that children need both a mother and a ... professor of sociology and of social and cultural analysis at ...
... ... ... 27, 2010 -- Epocrates, Inc. and RealCME announced today ... an advanced technology platform that addresses the needs of CME providers, supporters and health ...
... ... and 104E industrial computers.,Percon rejoins the AIDC and industrial computer industries with their release of ... data terminals or fixed mount computers are designed to operate in the harshest of environments. ... (PRWEB) January 27, ...
... Interest in whether ... New York, medical malpractice attorneys say. , ... New York, NY (PRWEB) January 27, 2010 -- Medical professionals of any kind ... standards of practice in the medical community. Unfortunately, a number of issues may compromise this ...
... ... with over 30 years combined experience in the hospitality industry. Their knowledge of writing ... Hakuna combines the mind of a manger with the speed and processing power of ... (PRWEB) January ...
Cached Medicine News:Health News:Lefkowitz, BBVA Foundation Frontiers of Knowledge Award in Biomedicine 2Health News:Lefkowitz, BBVA Foundation Frontiers of Knowledge Award in Biomedicine 3Health News:Are Two Mommies as Good as Mom and Dad? 2Health News:Are Two Mommies as Good as Mom and Dad? 3Health News:Are Two Mommies as Good as Mom and Dad? 4Health News:Epocrates and RealCME Unite to Deliver Enhanced e-Learning Offerings 2Health News:Epocrates and RealCME Unite to Deliver Enhanced e-Learning Offerings 3Health News:Percon Delivers Maximum Value in New Industrial Vehicle Computer Products 2Health News:Tired Doctors Need More Rest According to New York Medical Malpractice Attorney, David Perecman 2Health News:Tired Doctors Need More Rest According to New York Medical Malpractice Attorney, David Perecman 3Health News:Hakuna Staff Scheduling Software is Proud To Announce the Launch of Its Online Employee Scheduling Program 2
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... Sugar-Chex Linearity is a whole blood ... reportable range of the most popular ... recommendations of using a control matrix ... Linearity is packaged in ready-to-use dropper ...
Medicine Products: